This study assesses anti-AAV8 antibody levels using the AAV8 DetectCDx test in males with DMD (Duchenne muscular dystrophy). It enrolls male participants from 0 to under 25 years of age with a diagnosis of DMD. It is a study without an assigned phase and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Males at least 0 to \<25 years of age * Diagnosis of DMD * Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements Exclusion Criteria: * Prior participation in a gene therapy trial OR recipient of a gene therapy drug * Other inclusion/exclusion criteria apply